ZUMA-3 investigator, Bijal Shah presents interim phase I data on KTE-X19 (NCT02614066). The need for this investigational anti-CD19 CAR T cell therapy in adult patients with relapsed/refractory acute lymphoblastic leukemia and its mechanism of action are discussed alongside the results of this study.
1. What are the major unmet needs in the treatment of adults with relapsed or refractory acute lymphoblastic leukaemia? (0:04)
2. Could you tell us a little about KTE-X19 and its mechanism of action? (1:08)
3. What were the key inclusion and exclusion criteria of the ZUMA-3 study? (1:58)
4. What were the efficacy and safety findings of the interim analysis of phase 1 of ZUMA-3? (3:08)
5. Please could you tell us how you managed neurotoxicity in this study? (3:54)
Speaker disclosure: Bijal Shah has acted as a consultant for Adaptive Biotechnologies, received honoraria from Pharmacyclics/Janssen and research funding from Incyte and Jazz Pharmaceuticals.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Leukaemia
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia
At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia. Questions 1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05) 2. Following discontinuation of TKIs in patients with CML, when are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!